Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 8-K (Current Report)
Report Date: May 07, 2026
Reporting Period: Three months ended March 31, 2026
Context: The filing serves as a notification that the company issued a press release on May 7, 2026, announcing its financial results for the first quarter of 2026. The detailed results are contained in Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the press release (Exhibit 99.1) but are not present in the filing text itself.
Material Changes
No material changes or comparative financial data versus the prior period are disclosed in the text of this Form 8-K. The filing solely references the issuance of the Q1 2026 results.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the information in Item 2.02 and Exhibit 99.1 will not be treated as "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference unless expressly stated in another filing.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 7, 2026) for actual Q1 2026 financial figures.
- Verify the company's cash position and burn rate, as these are critical for a biotechnology firm but are not listed in this summary text.
- Check for any forward-looking guidance or clinical trial updates included in the referenced press release.
- Confirm the status of the redeemable warrants (REVBW) and their exercise price of $2,318,400 per share as listed in the securities section.